Bristol-Myers Squibb Company [NYSE: BMY] price plunged by -0.53 percent to reach at -$0.43. The company report on November 29, 2022 that Envisagenics Announces Research Collaboration with Bristol Myers Squibb.
Collaboration will leverage Envisagenics’ SpliceCore® AI platform for accelerated discovery and development of oncology therapeutic candidates.
Envisagenics, an Artificial Intelligence (“AI”)-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY). The multi-year collaboration will leverage Envisagenics’ SpliceCore® AI platform to identify alternative splicing derived targets for therapeutic development to expand Bristol Myers Squibb’s vast oncology pipeline. Envisagenics will receive an upfront payment and milestone payments based on development, regulatory, and commercial achievements.
A sum of 6790636 shares traded at recent session while its average daily volume was at 9.69M shares. Bristol-Myers Squibb Company shares reached a high of $81.42 and dropped to a low of $80.40 until finishing in the latest session at $80.70.
The one-year BMY stock forecast points to a potential upside of 0.22. The average equity rating for BMY stock is currently 2.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Bristol-Myers Squibb Company [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $80.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Credit Suisse have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 18, 2022. The new note on the price target was released on October 10, 2022, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another drop from $82 to $76, while Berenberg kept a Hold rating on BMY stock.
The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.44, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.66. The Price to Book ratio for the last quarter was 5.27, with the Price to Cash per share for the same quarter was set at 4.26. Price to Free Cash Flow for BMY in the course of the last twelve months was 21.02 with Quick ratio for the last quarter at 1.30.
BMY Stock Performance Analysis:
Bristol-Myers Squibb Company [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.97. With this latest performance, BMY shares gained by 2.83% in over the last four-week period, additionally plugging by 7.24% over the last 6 months – not to mention a rise of 43.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 67.93, with the RSI for the last a single of trading hit 70.17, and the three-weeks RSI is set at 65.55 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 75.01, while it was recorded at 80.40 for the last single week of trading, and 73.94 for the last 200 days.
Insight into Bristol-Myers Squibb Company Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +20.57 and a Gross Margin at +57.69. Bristol-Myers Squibb Company’s Net Margin is presently recorded at +15.08.
Return on Equity for this stock inclined to 18.96, with Return on Assets sitting at 6.14.
Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
BMY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 4.14%.
Bristol-Myers Squibb Company [BMY] Insider Position Details
There are presently around $132,693 million, or 79.40% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 199,886,585, which is approximately 1.554% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 174,002,852 shares of the stock with an approximate value of $14.04 billion in BMY stocks shares; and JPMORGAN CHASE & CO, currently with $8.03 billion in BMY stock with ownership of nearly 1.778% of the company’s market capitalization.
Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,098 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 64,900,252 shares. Additionally, 1,173 investors decreased positions by around 77,012,572 shares, while 361 investors held positions by with 1,502,363,234 shares. The mentioned changes placed institutional holdings at 1,644,276,058 shares, according to the latest SEC report filing. BMY stock had 100 new institutional investments in for a total of 2,623,581 shares, while 132 institutional investors sold positions of 5,272,243 shares during the same period.